2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-118238
    Remeglurant 1309783-00-3 98%
    Remeglurant (MRZ-8456) acts as a selective, orally active and allosteric antagonist of the mGlu5 receptor, with an IC50 of 13 nM. Remeglurant (MRZ-8456) can be used in the research for dyskinesia in Parkinson’s disease (PD).
    Remeglurant
  • HY-118249
    GSK 1997132B 1168138-37-1 98%
    GSK 1997132B is a benzimidazole-based PPARγ partial agonist that can cross the blood-brain barrier with a pEC50 value of 8.0. GSK 1997132B has no significant effect on PPARα/δ. GSK 1997132B improves the problem of high blood clearance rate of earlier compounds, avoiding side effects such as weight gain and edema. GSK 1997132B can be used for research on Alzheimer's disease.
    GSK 1997132B
  • HY-118256
    LSN2814617 1313498-17-7 98%
    LSN2814617 is an orally active, potent, brain-penetrant, and selective mGlu5 (metabotropic glutamate 5) positive allosteric modulator (PAM), with EC50 values of 52 nM (Human mGlu5) and 42 nM (rat mGlu5). LSN2814617 shows wake-promoting effect. LSN2814617 can be used for schizophrenia research.
    LSN2814617
  • HY-118259
    L-663581 122384-14-9 98%
    L-663581 (FG-8205) is an agonist of benzodiazepine receptor, acting as a partial agonist at GABA A receptor.
    L-663581
  • HY-118308
    AHN-683 143934-15-0 98%
    AHN-683 is a luciferin-derived ligand that targets the peripheral benzodiazepine receptor (BDR).
    AHN-683
  • HY-118347
    Aspartame acesulfame 106372-55-8 98%
    Aspartame acesulfame is a methyl ester of a dipeptide. Aspartame acesulfame can be used as a synthetic nonnutritive sweetener. Aspartame acesulfame is composed of phenylalanine (50%), aspartic acid (40%) and methanol (10%).
    Aspartame acesulfame
  • HY-118350
    FR 75513 127975-78-4 98%
    FR 75513 is a 1,1'-biphenyl-2,6-dicarboxylic acid diester series compound that can inhibit the contraction of the detrusor muscle of guinea pig bladder (IC50=3.3 μg/mL). After intravenous injection of FR 75513 into anesthetized rats, it also showed strong inhibitory activity on the detrusor contraction (ID50=0.04 mg/kg).
    FR 75513
  • HY-118352
    LB-205 1113025-86-7 98%
    LB-205 is a pan-histone deacetylase inhibitor (HDACi). LB-205 can be used for the research of acute traumatic brain injury.
    LB-205
  • HY-118363
    Lu AE51090 1186229-95-7 98%
    Lu AE51090 is selective muscarinic M1 receptor agonist with blood-brain barrier penetration. Lu AE51090 activates human M1 receptor with EC50 of 61 nM, while showing no significant agonism at M2-M5 receptors. Lu AE51090 exerts procognitive effects in mice. Lu AE51090 can be used for the study of Alzheimer’s disease (AD) and cognitive impairment associated with schizophrenia (CIAS).
    Lu AE51090
  • HY-118387
    AVE-0118 498577-53-0 98%
    AVE-0118 is a nonselective Kv1.5 blocker with an IC50 of 1.1 μM. AVE-0118 is a multichannel inhibitor with weak, micromolar activity against Kv1.5 and other ion channels. It is inactive against IKs, IKATP, and L-type Ca+ channels.
    AVE-0118
  • HY-118402
    PD 119819 105277-43-8 98%
    PD 119819 is a highly selective benzopyran-4-one brain dopamine autoreceptor agonist. PD 119819, a heterocyclic piperazine, inhibits spontaneous locomotor activity and brain dopamine synthesis.
    PD 119819
  • HY-118406
    Ethybenztropine 524-83-4 98%
    Ethybenztropine (Ponalid) is a muscarinic receptor blocker. Ethybenztropine is an anticholinergic and antihistaminergic agent.
    Ethybenztropine
  • HY-118407
    LY56110 26766-37-0 98%
    LY56110 is an orally active aromatase inhibitor. LY56110 inhibits P-450-dependent p-nitroanisole O-demethylation and ethylmorphine N-demethylation in hepatic microsomes isolated from rat, with the IC50 of 2.5 and 11 μΜ, respectively. LY56110 can be used for neurological disorder study.
    LY56110
  • HY-118414
    20-Ethyl prostaglandin E2 37492-24-3 98%
    20-Ethyl prostaglandin E2 (compound 62) is a PG analog that stimulates Nurr1-dependent transcriptional activity.
    20-Ethyl prostaglandin E2
  • HY-118450
    FR260010 free base 374555-75-6 98%
    FR260010 free base is a selective 5-HT2C receptor antagonist, with a Ki value of 1.1 nM.
    FR260010 free base
  • HY-118455
    MRS1097 185259-16-9 98%
    MRS1097 is a potent antagonist of adenosine hA3 receptor, with the Ki of 100 nM.
    MRS1097
  • HY-118461
    PD 120697 108351-91-3 98%
    PD 120697 is an orally active dopamine (DA) agonist. PD 120697 inhibits striatal DA synthesis, DA neuronal firing, spontaneous locomotor activity, and reverses Reserpine (HY-N0480)-induced depression.
    PD 120697
  • HY-118463
    Benzomalvin A 157047-96-6 98%
    Benzomalvin A is a potent antagonist of neurokinin receptor isolated from Penicillium sp. Benzomalvin A shows inhibitory activity against substance P with Ki values of 12, 42 and 43 μM at the guinea pig, rat and human neurokinin NK1 receptors, respectively.
    Benzomalvin A
  • HY-118482
    Sauristolactam 128533-02-8 98%
    Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells. Sauristolactam also inhibits the receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and has the potential to inhibit osteoclast differentiation.
    Sauristolactam
  • HY-118489
    L644711 81997-33-3 98%
    L644711 is an anion transport inhibitor that reduces cell swelling by inhibiting potassium-activated D-aspartate release in astrocytes. L644711 can be used in the study of brain injury and neuroprotection.
    L644711
Cat. No. Product Name / Synonyms Application Reactivity